Adamas' Series D Round Brings In $40 Million For Combination Antiviral Against Flu
This article was originally published in The Pink Sheet Daily
Private firm begins unveiling itself gradually, including plans for a triple-combination antiviral drug therapy for severe flu.
You may also be interested in...
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.